FLT4 and neoplasm: In this context, we investigated the effects of fruquintinib, a selective oral VEGFR3/FLT4/CD310 inhibitor with high affinity for VEGFR3/FLT4/CD310, on tumor growth and size on colorectal (MC38, CT26) and breast (4T1, E0771) tumors.